These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 10628595

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cyclooxygenase inhibition: between the devil and the deep blue sea.
    Hawkey CJ.
    Gut; 2002 May; 50 Suppl 3(Suppl 3):III25-30. PubMed ID: 11953329
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).
    Wallace JL.
    Am J Med; 1999 Dec 13; 107(6A):11S-16S; discussion 16S-17S. PubMed ID: 10628589
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rationalizing cyclooxygenase inhibition for optimization of efficacy and safety profiles. Proceedings of a workshop. Fort Worth, Texas, USA. February 1999.
    Am J Med; 1999 Dec 13; 107(6A):1S-89S. PubMed ID: 10628587
    [No Abstract] [Full Text] [Related]

  • 9. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent.
    Harirforoosh S, Aghazadeh-Habashi A, Jamali F.
    Clin Exp Pharmacol Physiol; 2006 Oct 13; 33(10):917-24. PubMed ID: 17002668
    [Abstract] [Full Text] [Related]

  • 10. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events.
    Freston JW.
    Am J Med; 1999 Dec 13; 107(6A):78S-88S; discussion 89S. PubMed ID: 10628597
    [Abstract] [Full Text] [Related]

  • 11. [Therapy with preferential and specific COX-2 inhibitors].
    Stichtenoth DO, Frölich JC.
    Internist (Berl); 2001 Mar 13; 42(3):421-6. PubMed ID: 11277028
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G, Panzetta G.
    G Ital Nefrol; 2002 Mar 13; 19(2):199-203. PubMed ID: 12195419
    [Abstract] [Full Text] [Related]

  • 15. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials.
    Schoenfeld P.
    Am J Med; 1999 Dec 13; 107(6A):48S-54S. PubMed ID: 10628593
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
    Houben JJ, Liem B.
    Ned Tijdschr Geneeskd; 1999 Nov 13; 143(46):2338. PubMed ID: 10589225
    [No Abstract] [Full Text] [Related]

  • 20. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
    Atkinson HG.
    Health News; 2002 Aug 13; 8(8):5. PubMed ID: 12206146
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.